# Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

> **NCT00354549** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 104 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** bevacizumab + erlotinib hydrochloride
- **DRUG:** gemcitabine hydrochloride + cisplatin or carboplatin

## Key facts

- **NCT ID:** NCT00354549
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-04
- **Final completion:** 2010-09
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354549, "Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00354549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*